alexa Recurrent Ovarian Cancer |OMICS International| Chemotherapy: Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recurrent Ovarian Cancer

In spite of recent progress in treatment strategies, 70% of advanced stage ovarian cancer cases relapse. Patients with recurrent disease are commonly characterized as platinum sensitive or platinum resistant. The definition of platinum-resistant disease includes patients who progress while receiving initial chemotherapy or within 6 months of completing initial platinum-based chemotherapy. If platinum free interval is less than 3-month, patients are defined as refractory disease and they have very little chance to respond to a platinum-based therapy. Platinum-sensitive patients are defined by recurrence after 6 or more months of the completion of initial chemotherapy. For a better subdivision of platinum sensitive group, patients with a more than 12-month interval are defined as highly sensitive disease and patients with 6 to 12 months are considered intermediate sensitive disease. Response to platinum retreatment increases with a longer interval from prior platinum treatment.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on June, 2014

Top